Welcome to article directory Institut Hartheim. Here You can find interesting and useful information on most popular themes.

There are 419 published articles and 1553 registered authors in our article directory.

Recent Articles

Actos Side Effects Legal Report

By admin | Published January 26, 2012

Actos Side Effects:  When applied to TCC, the term “superficial” can be misleading, and some doctors would like to see the term discontinued. Many people equate the term “superficial” with “not very risky,” which isn’t always the case. In general, superficial TCC at the low or intermediate risk levels is a highly treatable form of bladder cancer with a good chance for an excellent outcome despite a moderate to high rate of recurrence (depending on the extent and nature of the tumor). But as we discussed in Chapter 3, some superficial TCCs are considered high risk and cariy an elevated chance that the cancer will not onfy recur, but may have progressed to a more dangerous stage when it does recur.

Luckily, only about 20 percent of those who experience a recurrence are diagnosed with a more advanced type of bladder cancer. What this means is that “superficial” bladder cancer, if and when if recurs, will usually come back again as a superficial cancer that can be managed by local means. However/ understanding your prognosis and being informed about the cancer’s possibility of recurrence are important parts of your overall treatment process.

Make sure that your multidisciplinary team – which may include your urologist, oncologist, pathologist, and radiation oncologist – welcomes your active involvement in your treatment plan and thoroughly explains each step of the process to you. It is worth mentioning that noninvasive bladder cancer is usually managed by a urologist with support from the pathologist and usually does not require a full multidisciplinary team unless it recurs repeatedly.

More information on Actos Side Effects

Most likely at this point you’ve undergone some of the diagnostic tests discussed in Chapter 2.YouVe had tissue biopsied and classified as superficial TCC, and you probably underwent a flexible cystoscopy, during which your doctor thoroughly examined your bladder wall and made a “map” of the location of abnormal tissue or tumors that other diagnostic tests have confirmed. Sometimes more than one tumor will be present in the bladder, so your urologist will be veiy careful to look at the whole organ from the inside. The next step for you is likely to be resection (removal of the tumor), unless youVe already had a surgical biopsy or rigid cystoscopy. In that case, your doctor may have done a resection to avoid your having to undergo a second surgical procedure under anesthesia.

Undergoing a resection sounds more intimidating than it actually is. Think of it as the removal of the piece of the bladder where the tumor or abnormal cells are growing. This may effectively clear the bladder of tumor, bringing it to a state where only healthy tissue remains. When you have a bladder resection by means of a cystoscopy, as opposed to invasive surgery, you won’t have an incision or stitches, as no external cutting or incision is required.

Resecting (sometimes called endoscopic resection) is performed under general anesthesia in a hospital setting. Your doctor will use a resectoscope, which resembles a somewhat larger cystoscope. Like a cystoscope, it has a lighted lens and is introduced into your bladder through your urethra. (Don’t worry; you’ll be asleep under anesthesia and receiving pain medication while this is happening.)

Information from other sources on Actos Side Effects

Your doctor will fill your bladder with water or a nonirritating clear liquid such as glycine, which expands the bladder walls and makes it easier to see tumors and abnormalities. Guided by the map made during the initial cystoscopy your doctor will use a small wire loop (through which a high-energy electrical current runs) to remove the cancer, a margin of healthy tissue, and a small amount of muscle. Any remaining cells are removed with an electric current or sometimes a high-powered laser. Sometimes your doctor will also take a few random tissue samples from other areas of your bladder to make sure that abnormal cells aren’t developing elsewhere. The tumor, healthy tissue, and muscle are then sent to your pathologist for examination. A small amount of muscle tissue is included in the tissue sample so that the pathologist can make sure the tumor hasn’t spread into the muscle wall. A margin of healthy tissue is taken to help decrease the chances that abnormal cells remain in the bladder.

Resection is usually carried out as outpatient surgery. This means that you probably will be able to go home the same day. (You’ll need to bring a driver with you as you’ll still be recovering from anesthesia and won’t be sufficiently alert to drive a car.) You may have some blood in your urine for a few days after a resection, and you may experience pain or stinging upon urination. The stinging urination can be eased by drinking lots of fluids and by taking simple pain medications prescribed by your urologist. If either condition lingers longer than two or three days, if other painful conditions occur, or if the bleeding becomes extensive, call your doctor right away.

In some circumstances, your doctor may choose to insert a catheter into your bladder for a short time (usually only one to two days) after the surgery, to prevent blood clots from obstructing the flow of urine and causing discomfort. The catheter allows blood and urine to gently drain out of the bladder and also allows your doctor to irrigate your bladder to promote complete healing of the resected area. On rare occasions, doctors will recommend another resection procedure. Sometimes the pathologist wants to biopsy muscle tissue from deeper in the bladder wall. And sometimes the tumor is too large to be safely removed all at once.

Our use of the term or terms Actos Side Effects is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Actos Side Effects visit our site often.

Actos Side Effects

Posted in Emerging Mass Torts | Tagged |

Actos Cancer Update

By admin | Published January 26, 2012

Actos Cancer: For invasive bladder cancer, chemotherapy is sometimes given before a cystectomy. Sometimes it is given afterward. Sometimes it is not given at all. It depends entirely on the type of tumor you have, where it may have spread, and whether you have another medical condition that might make it difficult for you to tolerate chemotherapy. Very advanced age can also be a factor in deciding whether che­motherapy is appropriate.

The choice of drugs used to treat invasive bladder cancer is similar to the choice in advanced or metastatic disease, and we will cover that in chapter 6. If you have invasive uro­thelial carcinoma, you will probably undergo chemotherapy, because this type of cancer is responsive to either radiother­apy or surgery with chemotherapy, and many studies have examined this type of cancer treatment. If you have been diagnosed with squamous cell can­cer or adenocarcinoma, the outcome for chemotherapy is not so clearly defined. Most physicians don’t recommend chemotherapy as standard treatment in conjunction with cystectomy for these types of cancer. It is, however, quite reasonable for your team to suggest that you look into a clinical trial (e.g., one that is exploring the use of chemo­therapy) if you have been diagnosed with squamous cell or adenocarcinoma.

For more information on Actos Cancer follow us on our RSS Feeds.

For invasive urothelial carcinoma, most of the informa­tion from clinical trials has been obtained from patients who were initially given chemotherapy by intravenous injection and who then went on to cystectomy or to definitive radio­therapy. Most of the reported trials indicate that the use of single chemotherapy drugs does not have an extensive beneficial effect, but that the use of combinations of three or four chemotherapy drugs can shrink the bladder cancer in about 70 percent of cases. The drugs can also improve the cure rate and length of survival.

For you as a patient, the information gleaned from these clinical trials means that if you have urothelial cancer, your doctors are likely to recommend treatment that includes a cocktail of several carefully targeted chemotherapy drugs as well as cystectomy or radiotherapy. With some cancers, such as breast cancer, it is fairly standard practice to give several doses of chemotherapy after surgery, especially for tumors with high-risk pathologi­cal features, such as lymph-node involvement. We know of six studies that have examined the question of when che­motherapy should be administered for best outcome with bladder cancer, but the results are somewhat inconclusive about whether chemotherapy is most effective if given before or after surgery.

A large randomized trial is in progress in Europe to study whether intravenous chemotherapy after cystectomy improves the cure rate. Until the results of that study are available, most medical teams recommend consideration of first-line chemotherapy, followed by cystectomy, for deeply invasive bladder cancer. Sometimes a cystectomy reveals a cancer that is deeper or more extensive than had been expected; in that situation, the urologist or oncologist will usually discuss the benefits and drawbacks of using chemo­therapy after surgery (called adjuvant chemotherapy), typi­cally with the same drugs that would have been given before surgery.

Information from other sources on Actos Cancer

Following are descriptions of some common chemother­apy combinations. This is not an exhaustive list. Talk with your doctor about your treatment plan. Remember that not all people experience all side effects. Your general health, age, other drugs you might be taking, and the dosage of the chemotherapy drugs may affect what side effects you experience. Many side effects are unpleasant, but they are temporary, and the severity of effects is variable. Some side effects are more serious, and you should talk with your med­ical team about them.

Our use of the term or terms Actos Cancer is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Actos Cancer visit our site often.

Actos Cancer

Posted in Emerging Mass Torts | Tagged |

Actos Lawsuits Headlines

By admin | Published January 26, 2012

Actos Lawsuit: For invasive urothelial carcinoma, most of the informa­tion from clinical trials has been obtained from patients who were initially given chemotherapy by intravenous injection and who then went on to cystectomy or to definitive radio­therapy. Most of the reported trials indicate that the use of single chemotherapy drugs does not have an extensive beneficial effect, but that the use of combinations of three or four chemotherapy drugs can shrink the bladder cancer in about 70 percent of cases. The drugs can also improve the cure rate and length of survival. For you as a patient, the information gleaned from these clinical trials means that if you have urothelial cancer, your doctors are likely to recommend treatment that includes a cocktail of several carefully targeted chemotherapy drugs as well as cystectomy or radiotherapy.

With some cancers, such as breast cancer, it is fairly standard practice to give several doses of chemotherapy after surgery, especially for tumors with high-risk pathologi­cal features, such as lymph-node involvement. We know of six studies that have examined the question of when che­motherapy should be administered for best outcome with bladder cancer, but the results are somewhat inconclusive about whether chemotherapy is most effective if given before or after surgery.

A large randomized trial is in progress in Europe to study whether intravenous chemotherapy after cystectomy improves the cure rate. Until the results of that study are available, most medical teams recommend consideration of first-line chemotherapy, followed by cystectomy, for deeply invasive bladder cancer. Sometimes a cystectomy reveals a cancer that is deeper or more extensive than had been expected; in that situation, the urologist or oncologist will usually discuss the benefits and drawbacks of using chemo­therapy after surgery (called adjuvant chemotherapy), typi­cally with the same drugs that would have been given before surgery.

Following are descriptions of some common chemother­apy combinations. This is not an exhaustive list. Talk with your doctor about your treatment plan. Remember that not all people experience all side effects. Your general health, age, other drugs you might be taking, and the dosage of the chemotherapy drugs may affect what side effects you experience. Many side effects are unpleasant, but they are temporary, and the severity of effects is variable. Some side effects are more serious, and you should talk with your med­ical team about them.

For more information on Actos Lawsuit follow us on our RSS Feeds.

Radiation uses radioactive beams or pellets to kill cancer cells. Your medical team may recommend a course of radia­tion therapy in addition to chemotherapy and/or surgery. Radiation therapy for bladder cancer is commonly deliv­ered with a machine that focuses an invisible external beam on die area that requires treatment. The procedure is painless and similar to having an ordinary X-ray done. In the usual approach, your doctors will use your CT scan as a road map of your abdomen and pelvis to pinpoint your tumor and aim the beam at it. In another type of radiotherapy, doc­tors implant a small pellet or needle of radioactive material directly into your cancer. (This is rarely used for bladder cancer these days.)

When radiation is used alone or with chemotherapy, there is an increased likelihood that your other organs, such as the prostate and uterus, will remain functional, as does your ability to void urine normally and have sex. The intention when chemotherapy ^¿radiotherapy are given is usually to improve the chances of curing the cancer while preserving the bladder and avoiding the need to remove it surgically. This area is still somewhat controversial; some physicians believe that this approach is nearly as effective as surgical removal of the bladder, but others feel that cystec­tomy is the best treatment. The decision of which treatment to pursue depends in part upon the physical fitness of the patient as well as upon the patients personal preferences.

Information from other sources on Actos Lawsuit

Radiotherapy is not without side effects. Radiation can scar bladder tissue, and the scarring can reduce the amount of urine your bladder can hold as the bladder wall becomes less distensible. As a result you may experience an increase in the number of times you have to urinate, which can be irritating, especially at night. You also may experience an increase in bouts of cystitis.

There has been much discussion in the medical commu­nity about whether the results achieved by radiotherapy are the same as those from cystectomy with respect to achieving cure. We think that when one considers all types of blad­der cancer, in the hands of a highly experienced urologist who specializes in this operation, cystectomy gives better results than radiotherapy. However, there are some patients, particularly those with other significant medical conditions, who will benefit from radiotherapy, despite the possibility of a lower chance of permanent cure. In some centers, such as Massachusetts General Hospital, where the techniques of chemo radio therapy and bladder preservation have been piloted, a urologist will perform a cystoscopy about halfway through the planned course of radiotherapy. If the tumor is shrinking well, radiotherapy will be completed. However, if it appears that the cancer is not responding to radiother­apy, the plan will be abandoned and replaced with a radical cystectomy.

Our use of the term or terms Actos Lawsuit is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Actos Lawsuit visit our site often.

Actos Lawsuits

Posted in Emerging Mass Torts | Tagged |

Actos Attorneys Resources

By admin | Published January 26, 2012

Actos Attorneys: The exact mechanism(s) of BCG is still not fully understood. It is known BCG actually attaches to and enters cancer cells. BCG is thought to trigger an increased immune reaction in the bladder, thereby killing off cancer cells. BCG is held in the bladder for two hours. One should not hold it longer as adverse reactions are increased. The individual should then void into a toilet at home, preferably in a seated position to avoid splashing. After voiding, the toilet is disinfected with bleach. Since BCG can be shed from the urethra after treatment for several days, condoms should be used or one should abstain from sexual relations for at least 48 hours after treatment.

Studies have shown an approximately 40% reduction in tumor recurrence in those treated with BCG as compared with those without treatment.For those with CIS, the reduction is even greater at approximately 70%. For individuals with residual tumors after resection, complete response is generally about 60%.Despite intravesical therapy, ultimately between 10-20% of individuals with superficial bladder cancer will develop muscle invasive disease.

After a 6 week induction course of weekly BCG, treatment is often repeated with 3 weekly treatments at 3 months, 6 months and then every 6 months for up to 3 years. This regimen was shown to decrease recurrences and increase complete responses as compared to induction treatment alone. Unfortunately, despite initial success, over long periods of time, many will experience disease recurrence and progression.Treatment regimens can be individualized based on the patient’s progress and his adverse reactions to treatment, which generally increase with repeated cycles.

For more information on Actos Attorneys follow us on our RSS Feeds.

Adverse reactions are side effects of treatment. Approximately 95% of individuals will tolerate treatments well. Adverse reactions may be mild. Common reactions include cystitis (inflammation of the bladder characterized by burning on urination), hematuria, mild fever, malaise, and nausea. These symptoms generally pass without any treatment. For bothersome symptoms, various medications may prove helpful. Your physician can prescribe medication for burning or urinary frequency. For those with persistent cystitis, antibiotics can be utilized. For individuals experiencing severe symptoms lasting more than 48 hours, isoniazid, an anti-tuberculous drug can be prescribed. A short course of 3 days, starting the day before the next dose of BCG can be used to prevent severe side effects. Fortunately severe reactions resulting in sepsis, a life threatening condition characterized by high fever, chills and drop in blood pressure, is exceedingly rare. Sepsis would be treated in a hospital with triple anti-tuberculous drugs, steroids, and broad spectrum antibiotics.

Information from other sources on Actos Attorneys

As treatment cycles progress, generally adverse reactions increase in severity, the most common being cystitis. Patients should not receive additional doses until they are asymptomatic. Studies have demonstrated increasing the intervals between treatments and reducing the dose of the BCG can still result in perhaps equal efficacy, but with reduced toxicity. BCG therapy results in marked inflammation of the bladder wall. Cystoscopy done too soon after therapy would reveal a markedly reddened surface, making finding a bladder tumor difficult. Furthermore, microscopically, there will be severe reactive changes, complicating the pathologist’s job, as deciding between changes from the BCG and recurrent cancer, would be extremely difficult.

Recurrence of bladder cancer after the initial induction course, or relapse after complete response, would indicate failure of therapy. When two or more courses result in recurrence or when recurrence develops during the first six to twelve months after induction and maintenance therapy, patients generally are felt to have disease which is at higher risk for progression. A high percentage of patients who are complete responders remain tumor free for up to five years. However, with the passage of more time, additional patients will have late recurrences. For those with late recurrences (two to three years after therapy), most will respond to repeat BCG therapy.

Our use of the term or terms Actos Attorneys is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Actos Attorneys visit our site often.

Actos Attorneys

Posted in Emerging Mass Torts | Tagged |

Actos Lawyer Statement

By admin | Published January 26, 2012

Actos Lawyer: Ultrasonography can check for a kidney tumor, stone, or obstruction. Bladders filled with urine can be scanned. There is no contrast or X rays involved, and therefore the study can be accomplished in those with renal disease, contrast allergies or for women who are pregnant. Although larger tumors of the bladder are often visible, it is not a good study to rule out urothelial cancer (transitional cell cancer of the urinary tract lining) since smaller tumors or flat tumors in the lining are not visible. Also, other conditions such as enlarged folds in the bladder or enlarged prostates can be confused with bladder tumors. Ultrasound exams are generally fast, painless, and relatively inexpensive. An ultrasound combined with cystoscopy plus cytology (to rule out cancer cells) is a reasonable assessment for those with a low likelihood of having upper tract disease.

CT Scan or CAT (computerized axial tomography) provides a computerized cross sectional visualization of the abdomen and pelvis. X ray images are synthesized into exquisitely detailed images. The CT scan can be done with or without IV contrast, and therefore has the same limitations as IVP in those with allergies to contrast or renal insufficiency. These studies are excellent for finding renal cell cancers and stones within the kidneys and ureter, but not very good at delineating cancers of the lining. CT scan is often an important part of staging bladder cancer, determining whether the cancer has spread.

For more information on Actos Lawyer follow us on our RSS Feeds.

Magnetic Resonance Imaging (MRI) is a technology which uses strong magnets to provide detailed images of your internal organs. Like ultrasound, this study has no known harmful effects on the body. It does not require contrast injection like CT scan and can be done safely in patients with renal insufficiency. It is not generally used for initial screening. Many individuals find the test uncomfortable due to a loud noise heard throughout the test, in addition to the close quarters the machine requires, leading to feelings of claustrophobia. A mild sedative may be required if the test is necessary and the individual experiences these uncomfortable feelings.

Initial treatment may eradicate an individual’s bladder cancer, however, for many, recurrent tumors may develop. Up to 70% of individuals will have recurrent bladder cancer after initial therapy. In approximately one third of patients, not only will tumors recur, but they will become more serious over time, developing a higher grade or stage. This chapter will review the importance of staging bladder cancer, the single most important predictor of future problems. In addition, we will review other important indicators that impact the prognosis.

After the diagnosis of cancer is made, it is critical to establish the stage of the cancer. Cancer stage quantifies the extent of cancer in the individual. The number of tumors, their size, whether or not they have grown into the wall of the organ or spread beyond, all fit into the various stages of a particular cancer. Most cancers can be found at an early, nonlethal stage. As they grow and worsen, they can invade the wall of the organ they lodge in, spread locally through the organ into surrounding tissue, or spread throughout the body via the lymphatic or blood system.

Information from other sources on Actos Lawyer

In the case of bladder cancer, initial stage is critical in predicting the prognosis. For individuals with bladder cancer, recurrence (repeated tumors) is common. For many, progression (the development of higher grade, invasive or metastatic cancer) is also a real concern. By looking at the initial stage of the bladder cancer and restaging with each new cancer recurrence, the urologist can predict or prognosticate the possibility of the individual developing more life threatening invasive disease which has the ability to spread beyond the bladder and lead to death. Treatment options exist at each stage of cancer. It is the goal of the urologist to preserve your bladder as long as possible without jeopardizing your life with a cancer that may spread and become incurable.

Our use of the term or terms Actos Lawyer is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Actos Lawyer visit our site often.

Actos Lawyer

Posted in Emerging Mass Torts | Tagged |

Actos Lawsuit Advice

By admin | Published January 26, 2012

Actos Lawsuit : Cancer, including bladder cancer, develops because of changes in the DNA of a normal cell. DNA can be damaged by chemical exposures such as cigarette smoke, industrial chemicals, chemotherapy, and so forth. (See Questions 10 and 11.) Environmental exposures such as these are called risk factors. Risk factors do not exactly cause bladder cancer. Not everyone who smokes will get bladder cancer. However, as a group, the risk is ele­vated relative to people who do not smoke. Exposures such as these increase the likelihood of DNA becom­ing damaged. When the specific DNA that controls a cell’s growth is damaged, the cell then has the poten­tial to become cancerous. The hallmark of cancer is overgrowth of cells, causing compression of surround­ing tissues or destruction of the tissues.

Some risk factors, such as your genes, can­not be changed. Many more, however, can be changed. Cigarette smoking is the biggest risk factor for getting bladder cancer. If you are a smoker, the most impor­tant thing you can do is to quit today. If someone you live with smokes, encourage that person to quit also. Question 10 discusses what are called modifiable risk factors. These are the lifestyle and environmental things that you can change to decrease your chances of get­ting bladder cancer. Look over this list carefully, and do everything you can to change your lifestyle now to help protect your future and your family’s future.

As we alluded to previously here, not everyone has the same risk of developing cancer. By studying the charac­teristics of patients who have bladder cancer, researchers have been able to identify groups of people who seem to develop the disease more often than others. These groups of people each have some risk factor that they are born with, things that predispose them to cancer no matter how carefully they live their lives. In fact, our genetic makeup probably plays the biggest role in deter­mining who among us is destined to get cancer.

For more information on Actos Lawsuit follow us on our RSS Feeds.

Different races have different risks of bladder cancer. Caucasian (white) Americans are twice as likely to develop transitional cell cancer (the most common type of bladder cancer), as are African Americans. For the more rare type of bladder cancer, called squamous cell cancer, however, the reverse is true; African Americans are twice as likely to develop squamous cell cancer of the bladder than are white individuals. Of all the different races, Caucasians seem to have the highest rate of bladder cancer. Men are almost three times more likely to develop cancer than women. This is before taking into consideration modifiable risk factors such as smoking and workplace exposures to chemicals. More than 65% of bladder cancer occurs in patients who are older than 65. Patients in this age group are also more likely to develop more aggres­sive tumor types than are the younger bladder cancer patients.

Information from other sources on Actos Lawsuit

As you may remember from the prior dis­cussion, cancer develops only after something goes haywire in the regulatory process of cell growth or cell death. Several different genes normally accom­plish this regulation. In a normal, healthy cell, these genes promote growth or suppress growth or can even signal a cell to destroy itself in an appropriate situation. For a cell to become cancerous, many of these genes must be altered or destroyed simultane­ously. Nature has even supplied our cells with other genes that are able to repair damaged genes. These “repairmen” genes are known as tumor suppressor genes. Their job is to repair damaged DNA when possible or to drive a damaged cell to destroy itself.

Our use of the term or terms Actos Lawsuit is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Actos Lawsuit visit our site often.

Actos Lawsuit

Posted in Emerging Mass Torts | Tagged |

Vaginal Lawsuit Info

By admin | Published January 26, 2012

Vaginal Lawsuit : Early work wouLd suggest that some SERMs in development, eg levormeloxifene and idoxifene, might increase the risk of urogenital prolapse,53although there were some methodological problems noted in the study. However, in another analysis of three randomized, double­blind, placebo-controlled trials investigating raloxifene in 6926 postmenopausal women. Oestrogens are known to have an important physiological effect on the female Lower genital tract throughout adult life, leading to symptomatic, histological and functional changes. Urogenital atrophy is the manifestation of oestrogen withdrawal following the menopause, presenting with vaginal and/or urinary symptoms. The use of oestrogen replacement therapy has been examined in the management of lower urinary tract symptoms as well as in the treatment of urogenital atrophy. Only recently has this treatment been subjected to randomized placebo-controlled trials and meta-analysis.

Oestrogen therapy alone has been shown to have little effect in the management of USI. When considering the irritative symptoms of urinary urgency, frequency and urge incontinence, oestrogen therapy may be of benefit, although this may simply represent reversal of urogenital atrophy rather than a direct effect on the lower urinary tract. drugs appeared to have a protective effect – fewer treated women had surgery for urogenital prolapse. Finally, low-dose vaginal oestrogens have been shown to have a role in the treatment of urogenital atrophy in postmenopausal women and would appear to be as effective as systemic preparations.

For more information on Vaginal Lawsuit follow us on our RSS Feeds.

Incontinence can be cured or significantly improved in most women providing they are appropriately investigated and treated. However, some women may not wish to undergo medical or surgical intervention. There are also a number of women for whom a cure may be impossible. For this group, containment with pads, devices or even catheters may be the most appropriate therapy. Reported figures1 estimate the overall cost of incontinence to the NHS at £354 million, with the cost continuing to rise.2 Continence products are one of the biggest expenditures for the NHS today.

Products available are numerous, but it is important to match the product to the individual’s personal needs, wishes and social circumstances. It is difficult even for a specialist continence nurse to keep up with the choice available. Companies are constantly changing and developing their products, endeavouring to ensure that their products suit the requirements of the users. The pad is the most common and the most readily available form of containment. The market of reusable and disposable products has grown tremendously. In 1974 Bill Kylie, an Australian, launched an oblong absorbent pad that became the forerunner of the disposable pad industry. There are few quality trials to assess pads, and many products have frequently been replaced before the results are published.

Information from other sources on Vaginal Lawsuit

Pads should not be used as an alternative to effective continence promotion strategies. They should really be a temporary measure while investigations are undertaken or treatment is awaited. Pads should only be used as treatment in the severely incontinent person where containment will be a priority. Pads can either be disposable or reusable. There is no strong evidence that one is more effective than the other. The advantages and limitations of reusable and disposable products are outlined in Table 12.1. The commonest problem with disposable pads is that they can become bulky and the covering can even become separated if they are not replaced when needed.

The decision whether or not to use reusable incontinence products rather than disposables is a complex one that will depend on individual needs and preferences. The availability of suitable laundry facilities is an important factor. Over a thousand items, ranging from special toilet seats to assist toilet training to odour-control products are listed in The United Kingdom Continence Foundation Product Directory.

In recent years there has been a wide variety of new continence devices developed.7 Although interest continues with clinicians and patients, many of the devices have never made it onto the market or have been removed from the market shortly after release. Some products are available on the Internet, but until these products become more widely available, they will continue to be limited to specialist units in controlled trials.

Our use of the term or terms Vaginal Lawsuit is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Vaginal Lawsuit visit our site often.

Vaginal Lawsuit

Posted in Emerging Mass Torts | Tagged |

Actos Lawsuit Report

By admin | Published January 26, 2012

Actos Lawsuit : There are two broad types of cancers in the bladder: primary and metastatic. Primary bladder cancers are those that begin in the bladder itself. Metastatic cancers are those that originated in another organ and then spread to the bladder. Other tumors can get into the bladder through the bloodstream, through the lymphatic system, or by directly extending from a nearby organ, such as the prostate or the cervix.

Cancers originating in the bladder are far more common than cancers that spread to the bladder from another loca­tion. There are several types of primary tumors. Recall that transitional cell cancer accounts for at least 90% of all bladder cancers. Transitional cell tumors can be classi­fied as (1) papillary, (2) sessile, or (3) a mix of both types. Papillary tumors look like a piece of cauliflower attached to the wall by a short stalk; sessile tumors look flat and are broad-based. Almost 70% of transitional cell tumors are papillary types, which tend to have a better prognosis than sessile tumors. Less common types of bladder can­cer include squamous cell cancer, adenocarcinoma, and urachal carcinoma.

For more information on Actos Lawsuit follow us on our RSS Feeds.

Squamous cell carcinoma accounts for 3% to 7% of bladder cancers in the United States; however, in Egypt it accounts for 75% of the bladder cancers. There is a parasitic infection called schistosomiasis that is very common in Egypt. Infection with this parasite strongly predisposes a person to the development of squamous cell cancer. The parasite burrows into the wall of the bladder, which chronically irritates the bladder. Over many years, this chronic irritation can lead to the devel­opment of bladder cancer, most often squamous cell cancer. Other conditions that cause chronic irritation also predispose to this type of tumor. Chronic indwelling catheters, for example, can irritate the bladder and pre­dispose someone to this tumor. Squamous cell carci­noma does not tend to spread to the lymph nodes like transitional cell cancer does, although it does tend to spread aggressively directly through the bladder into neighboring structures. Because it is so locally aggres­sive and relatively resistant to chemotherapy or radia­tion, it usually has a worse prognosis than transitional cell cancers.

Information from other sources on Actos Lawsuit

Adenocarcinoma of the bladder is quite uncommon, accounting for approximately 2% of all bladder cancers in the United States. These tumors are also associated with chronic irritation. They tend to be high-grade aggressive tumors and are therefore usually associated with a worse prognosis. Urachal carcinoma is a specific type of adenocarci­noma of the bladder, but it is unique in that it does not originate in the lining of the bladder. These develop from the outer surface of the bladder, extending toward the inside of the bladder. They can then metastasize to the lymph nodes, the liver, lung, and bone.

Our use of the term or terms Actos Lawsuit is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Actos Lawsuit visit our site often.

Actos Lawsuit

Posted in Emerging Mass Torts | Tagged |

Safyral Lawsuit News

By admin | Published January 26, 2012

Safyral Lawsuit: A dry, nonproductive cough is frequently associated with ACEI therapy and can be attributed to kinin accumulation. Patients should be urged to continue therapy, if tolerable. An alternative ACEI should be attempted prior to substitution with an ARB. A rare, but well-known, risk associated with ACEI therapy is angioedema. This life-threatening adverse reaction is most com­monly acute in onset but may occur late in therapy. Re-exposure to ACEI is not recommended, therefore alternative therapies such as hydralazine and ISDN should be considered. Angioedema has also been associated with ARBs, thus switching from an ACEI should be done with extreme caution.

Aldosterone antagonists are yet another class of agents available to target the RAAS. Sodium and water retention, hypokalemia, fibrosis, and ventricular remodeling are all consequences of excess aldosterone. The favorable effects of aldosterone antagonism in HF are due primarily to the inhibition of collagen deposition and fibrosis, therefore preventing ventricular remodeling. Spironolactone was the first aldosterone antagonist studied in the HF population. The RALES trial, which compared spironolac­tone to placebo, was halted early after a 30% relative risk reduc­tion in the primary endpoint of all-cause mortality was discovered during an interim analysis.11 Eplerenone, a selective aldosterone receptor antagonist, was studied in patients post-myocardial infarction with left ventricular dysfunction (EF < 40%).12 There was a significant reduction in mortality, risk of hospitalization due to HF, and sudden death due to cardiac causes. Unlike in the RALES trial, there were more cases of hyperkalemia and no differ­ence in gynecomastia in the eplerenone group.

For more information on Safyral Lawsuit: follow us on our RSS Feeds.

Diuretics are key ingredients in the successful management of HF patients. They are often necessary to combat the water and sodium retention elicited by angiotensin II and aldosterone. Diuretics allow for a rapid improvement in signs and symptoms of HF, such as peripheral edema, pulmonary congestion, and jugular venous pressure. These agents are often used long term to maintain symptomatic relief and improve exercise compliance. Although there have not been any clinical trials evaluating the effect of diuretics on mortality, they are indicated in all patients exhibiting signs and symptoms of volume overload.19 Diuretics should never be used alone to treat symptomatic HF. They should be used in combination with an ACEI and beta blocker to prevent further decompensation.

Diuretics, including loop and thiazide, prevent renal tubule absorption of sodium and water. Loop diuretics inhibit reabsorp­tion of sodium in the ascending limb of the Loop of Henle, while thiazide diuretics act in the distal convoluted tubule. Bumetanide, furosemide, and torsemide, all loop diuretics, increase sodium excretion by 20-25% whereas hydrochlorothiazide and metola- zone increase excretion by only 10-15%. It should also be noted that loop diuretics maintain efficacy in renal dysfunction while thiazides are less effective in patients with a creatinine clearance below 50 mL/min. Loop diuretics are, therefore, the most com­monly used diuretics in the management of HF.

Information from other sources on Safyral Lawsuit:

The surgical approach for left ventricular remodeling is predicated on the concept of restoring the geometry of the left ventricle to a conical shape. As shown below the left ventricle is opened in the area of dilatation or scar and direct inspection of the interior of the LV allows the surgeon to determine the beginning area of normal myocardium. This demarcation zone is used to fashion a new LV apex utilizing a constricting stitch and apical patch. The volume of the LV is determined by the patient’s preoperative LV dimensions and body surface area using a balloon template of known volume to adequately but not overly downsize the LV. Additional areas of thinning or dilatation can be plicated and the remaining LV scar is then closed to complete the repair.

Left ventricular failure secondary to myocardial cell dysfunction remains the pressing problem for the future and despite the uti­lization of surgical techniques and devices carries a significant long-term mortality. The future treatment of left ventricular fa.il- . ure may in large part reside in the new technologies surrounding the use of precursor cells growing in areas of myocardial scar or cellular dysfunction providing eventual improvement in left ven­tricular function. The use of stem cells, myoblasts, and skeletal muscle among others are currently under investigation utilizing tissue engineering by seeding cells in three-dimensional matrices of biodegradable polymers without artificial scaffolds to form new myocardial constructs. This technology of cell growth and cell implantation via vectors is well established but many questions are present and hopefully future answers will open this Pandora’s Box allowing successful treatment of end-stage heart failure.

Safyral Lawsuit: More information from other sources related to your search

One of the largest series of apico-aortic conduits in elderly high risk patients has been reported by Dr John Brown in which 45 elderly patients received valved conduits for risk factors men­tioned above. The procedure as pictured below is carried through a left thoracotomy and be accomplished without cardiopulmonary’ bypass in many cases. The operative mortality was low and mid­term durability of the prostheses was good allowing the conclu­sion that high risk elderly patients with no other option could be successfully palliated.

Initially carried out for compassionate use for extremely high risk patients, clinical trials are currently under way in the US and Europe to evaluate the percutaneous or apical implantation of an expandable aortic valve prosthesis. In view of the results of per­cutaneous AVR, the optimism expressed is premature. In fact, the only published series (6 patients affected by end-stage aortic stenosis), presented by Cribier and associates, evidenced some major drawbacks, such as perivalvular leakage, which is caused by the persistence of empty space between the percutaneous and native valves owing to calcifications and which was observed in the majority of patients. Moreover, coronary’ flow obstruction provoked by the valved stent and atheroembolism of calcific debris during the positioning of the derice is possible. Grube and colleagues have recently described 1 single case of implantation of self- expandable valve prosthesis by the retrograde approach, which was deemed to facilitate coaxial positioning and to reduce the risk of perivalvular leakage, but required extracorporeal circulatory support (ECC) as a “safety measure.”

Safyral Lawsuit: Additional News and Information about Keyword.

Certainly in the setting of acute RV failure, the underlying cause needs to be addressed to the extent possible. If treatment of the underlying etiology is unsuccessful or not possible, attempts should be made to maximize right ventricular performance. According to the Frank-Starling principle, volume loading may improve RV output (even in the setting of RV contractile dysfunc­tion). Invasive monitoring (central venous or pulmonary artery catheters) is often necessary to determine the optimal filling pres­sures because excessive volume loading may be detrimental to the RV contractile function. Inotropic support using agents such as dobutamine or milrinone may improve RV contractile function, especially in the setting of high pulmonary artery pressures. In few’ cases when RV failure persists despite optimizing function using the above strategies, right ventricular assist devices are required.

Currently, MCSDs are broken down into distinct types of pumps based on their design as well as there indications for use. Current FDA-approved indications for pump use include bridge-to-recov- ery, bridge-to-transplant, and permanent lifetime therapy. The type of pumps based on design can be either paracorporeal or intracorporeal in relation to the actual location of the pump. The pumps may be either pulsatile/displacement pumps or nonpulsa­tile continuous flow pumps inclusive of the rotary impeller type or centrifugal type. The pumps may have bearings or be bearing-less as in the totally magnetically levitated pumps. The utilization of the different systems is determined most notably by the clinical situation and specifically the ultimate goals of therapy. A single institution may have an array of different pumps that are utilized in different clinical scenarios. At our institution we typically divide the pumps into two groups – those intended for acute decompen­sated support and those for more elective implant for chronic heart failure. The ultimate goal of therapy is paramount to the specific device utilized being either short-term (days to weeks) or long-term (years) support in relation to the ultimate goals of recovery, transplant, or permanent lifetime therapy.

Safyral Lawsuit: More news about Safyral Lawsuit:

Total artificial heart pumps are orthotopically implanted and the native heart ventricles are excised. The first successful utiliza­tion of temporary total artificial heart was by Denton Cooley in 1969 utilizing a device developed by Liotta and DeBakey. The first permanent implant of a TAH system was done in 1982; a Jarvik-7 was implanted into Dr. Barney Clark by Dr. William DeVries at the University of Utah. Dr. Clark was supported on the Jarvik-7 for a total of 112 days. The S3>ncardia Cardiowest TAH-t system was approved as a temporary system for bridging to cardiac transplant by the FDA in 2004.Medicare approved reimbursement for the Syncardia Cardiowest TAH-t on 5/1/200S reversing its 1986 non­coverage policy for total artificial heart systems.

The goal of mechanical circulatory support is to restore normal physiologic blood flow to the body and prevent end-organ dys­function. In doing so the ventricle is unloaded thereby decreasing the myocardial workload and reducing the myocardial oxygen demand. Use of a VAD will reduce preload, myocardial wall ten­sion and oxygen consumption.15 Numerous studies have high­lighted the ability of MCSDs to adequately restore tissue perfusion and maintain as well as reverse end-organ dysfunction.

Our use of the term or terms Safyral Lawsuit: is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Safyral Lawsuit: visit our site often.

Safyral Lawsuit

Posted in Emerging Mass Torts | Tagged |

Actos Lawsuit Announcement

By admin | Published January 26, 2012

Actos Lawsuit: Pain post-op is initially treated often via the epidural catheter. Intravenous medication may be given as an alternative and switched to oral pain meds once the individual is tolerating liquids. Many physicians order a PCA (patient controlled anesthesia) in which the patient pushes a button that releases pain medication via an intravenous line into the blood stream. Maximal amounts of drug administered are carefully controlled by settings on the PCA to allow safe, effective analgesia.

During the post-o you will meet regularly with an enterostomy nurse who will teach you the mechanics of caring for an ostomy and handling the ostomy appliance.period, Gradually, your pain will diminish, strength will increase, and diet will be advanced. Drains placed intraoperatively to siphon off any excess fluids from the abdomen will be removed when no longer needed. During difficult dissection, small intestines may be inadvertently opened. These injuries are usually immediately recognized and repaired without difficulty. During removal of the bladder, the rectum may be entered. Assuming the patient has had a complete bowel prep prior to surgery, the rectum is usually readily repaired.

For more information on Actos Lawsuit follow us on our RSS Feeds.

During removal of the pelvic lymph nodes, entry into a major vein or artery may result in significant blood loss. Smaller, inconsequential veins or branches into larger veins are usually ligated with a suture or cauterized shut. Larger veins and arteries require repair with a fine vascular suture and needle. Troublesome bleeding can also occur during removal of the bladder and from deep in the pelvis after the bladder and prostate are removed. Bleeding is stopped through suture ligation, vascular clips, or cautery.

An abscess is a pocket of pus located deep within the body. It may form from a bowel or urine leak, and generally will require drainage since antibiotics alone may not resolve it. If percutaneous drainage (drainage through the skin) is possible, the radiologist will drain the abscess. If this is not possible, the urologist will need to open the incision or make a new incision to allow the pus to be drained. A sizable abscess will generally not be cured without proper drainage. Left untreated, an abscess can result in sepsis, a life threatening bacterial infection.

Information from other sources on Actos Lawsuit

When the bowel is reconnected after removing the section for the urinary diversion, healing may not be adequate and bowel contents may leak into the abdomen. A bowel leak often will present as a failure of the bowel to return to normal function, resulting in a distended abdomen with poor bowel sounds. Distention, ileus (poor bowel function) may occur after the bowels are working well and feeding has been going on for some time. Evaluation is usually accomplished with CT Scan and oral contrast. Immediate surgical correction may be necessary. Left untreated, a bowel leak will generally lead to an abscess or possibly a fistula (a drainage tract from the bowel which may extend out through the incision or drain). The incidence of bowel leak is increased if bowel has been exposed to prior radiation, most often from radiation used to treat prostate cancer in men and uterine cancer in women.

When a piece of bowel is separated from the intestine to create the new urinary drainage system, the remaining bowel must be reanastomosed (brought back together). This may be accomplished via sewing the bowel together or through the use of staples. Sometimes the opening of the bowel connection may be obstructed secondary to swelling. If an obstruction does not clear after a reasonable time, reoperation may be required.

During a standard radical cystectomy in the male, the fine nerves which run along the base of the prostate to the penis are severed, resulting in loss of erections (impotence). If the individual having surgery still has good erections and is sexually active, these nerves can be attempted to be saved by modifying the surgery. Saving the nerves is more difficult to do, it takes more time, and is not always successful.

Our use of the term or terms Actos Lawsuit is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Actos Lawsuit visit our site often.

Actos Lawsuit

Posted in Emerging Mass Torts | Tagged |